At Vertical Longevity Pharma, we're harnessing the power of virus-like particle (VLP) vaccines to eliminate senescent cells, one of the fundamental drivers of aging and chronic disease.

Preclinical senescent cell clearance has demonstrated therapeutic benefits across every organ system investigated, including curative potential for atherosclerosis, the world’s leading cause of death.

Engineered for stability at room temperature, our immunotherapy can remove the need for cold-chain logistics, enabling global accessibility and scalability even in low-resource settings.

If you share our vision for extending healthy human lifespan or have a personal connection to heart disease, follow along to see the results of our upcoming primate efficacy study.

Vertical Longevity Pharmaceuticals

Org chart

Teams

Offices